Reprogramming Tumor Microenvironment of Wild Type Glioblastoma by Cell Therapy Based on Interferon-Alpha Transduced Autologous TIE-2+ Macrophages: A Phase 1 Study in Newly Diagnosed GBM Patients
- Discussing the development of a novel cell therapy approach that uses modified macrophages to manipulate the tumor microenvironment in glioblastoma
- Highlighting the translation of a wild-type GBM strategy from the lab into a Phase 1 clinical trial, with a focus on how the therapy’s mechanism impacts patient outcomes
- Exploring the early-stage findings from this study and their implications for the future of GBM therapy, specifically through a patient-centric, immunotherapeutic approach